Skip to main content

SONDAS, SENSORES, NANOPARTICULAS BASADAS EN SILICE Y LIPIDOS Y DISPOSITIVOS MICROELECTRONICOS PARA TERAPIAS AVANZADAS Y DETECCION DE BIOMARCADORES.

PID2024-155683OB-C41

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para la Investigación y el Desarrollo Experimental
Subprogram Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2024
State Plan 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT POLITÈCNICA DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

  • Parés, Marta
  • Pallaruelo-Santamaría, Víctor
  • Fillat, Cristina
  • Martínez-Latorre, Javier|||0000-0001-5421-5371
  • Candela-Noguera, Vicente
  • Soriano-Teruel, Paula
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC. Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020- 119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from la Caixa Foundation under agreement LCF/PR/ SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Development of a novel dual fluorescent probe: mitochondrial targeting and iron chelator

  • Segura, Camilo
  • Yanez, Osvaldo
  • Urrutia, Pamela J.
  • Aguirre, Pabla
  • Quilaqueo, Maria
  • Nunez, Marco T.
  • Hinestroza, Juan
  • Aliaga, Margarita
  • Garcia-Beltran, Olimpo
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] We report the design, synthesis, and characterization of YBL-1, a coumarin-triphenylphosphonium (TPP+) fluorescent probe engineered for mitochondrial targeting and iron sensing. YBL-1 was obtained through a threestep sequence culminating in quaternization with (bromomethyl)triphenylphosphonium bromide. Steady-state photophysics reveal minimal solvatochromism (lambda abs 348-355 nm; lambda em 401-408 nm) and allowed transitions (epsilon max approximate to 2.2-2.6 & times; 104 M-1 cm-1). The probe remains bright in water, with high quantum yields (Phi F approximate to 0.76). Screening against common metal cations indicates a pronounced and selective turn-off response to Fe3+. Job's analysis supports 1:1 complexation, and Benesi-Hildebrand treatment (1:1 model) indicates a modest association constant on the order of 102 M-1 in water. Complementary quantum-chemical calculations support a predominantly it -> it* locally excited S1 state with only weak charge-transfer character, consistent with the small solvatochromism. Electrostatic potential maps and population analyses highlight the carbonyl/urea/alkoxy region as the primary hard-donor site, rationalizing Fe3+ binding; simple adduct models in water predict modest stabilization in line with the measured Ka and a rigidified complex consistent with static quenching. In SH-SY5Y cells co-stained with MitoTracker Red, YBL-1 colocalizes strongly with mitochondria (Pearson r approximate to 0.95), consistent with TPP+-driven membrane-potential-mediated accumulation. Complementary computations (DFT/ MEP) indicate robust electrostatic features and preferential stabilization in polar media, with the lowest relative energy in water. Together, these results establish YBL-1 as a water-bright, mitochondria-addressable fluorescent probe exhibiting selective Fe3+-responsive quenching suitable for live-cell imaging., This research was funded by FONDECYT Initiation in Research grant number 11201141, awarded to P.J.U. and by grant CVTUCH 2022-2 to M.T.N., O.G.-B. thanks funding from the Ministry of Science, Technology and Innovation, the Ministry of Education, the Ministry of Industry, Commerce and Tourism, and ICETEX, Programme Ecosistema Cientifico-Colombia Cientifica, from the Francisco Jose de Caldas Fund, Grand RCFP44842-212-2018. This research was also partially funded by project PROMETEO CIPROM/2021/007 from the Generalitat Valenciana and project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Targeted detection of Mycobacterium tuberculosis MPT64 antigen using an antibody-coated nanoporous anodic alumina biosensor: A novel approach for tuberculosis screening

  • Caballos, Isabel
  • Climent Terol, Estela
  • Gil-Brusola, Ana
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Aznar, Elena|||0000-0003-0361-3876
[EN] Tuberculosis (TB) is a chronic condition caused by Mycobacterium tuberculosis. According to WHO's Global Tuberculosis Report 2024, TB has again become the leading cause of death from a single infectious agent, surpassing COVID-19 in 2023 and 2024 in terms of infectious disease deaths. Due to its high infectivity and serious effects, timely diagnosis and treatment are crucial for controlling its spread. This study presents a fluorogenic biosensor for detecting M. tuberculosis MPT64 antigen using gated nanoporous anodic alumina (NAA). NAA material is loaded with rhodamine B and capped with an antibody against MPT64 protein. The presence of MPT64 induces antibody displacement due to the specific recognition and subsequent release of rhodamine B to the medium that is detected by fluorescence measurement. The biosensor is physicochemically characterized by scanning electron microscopy and X-ray spectroscopy. The biosensor achieves a limit of detection (LOD) of 1.32 nM (0.032 mg L-1) for MPT64 protein and demonstrated high selectivity through testing against various antigens from other viral pathogens and bacterial species. The efficacy of the biosensor is further validated with grown mycobacteria from clinical samples. The developed approach offers three key aspects: (i) selective detection of active TB by targeting the secreted MPT64 protein using gated nanomaterials; (ii) a rapid response (60 min); and (iii) a cost-effective design suitable for resource-limited settings. This biosensor shows great potential as a tool for the clinical diagnosis of active tuberculosis., We thank PID2024-155683OB-C41 and PID2021-126304OB-C41 from the Ministerio de Ciencia, Innovacion y Universidades and AEI/10.13039/501100011033 (co-financed by the European Regional Development Fund) , and CIPROM/2021/007 (to R. M.-M.) from the Generalitat Valenciana. This research was also supported by CIBER, Instituto de Salud Carlos III (group CB07/01/2012) . I.-C. thanks the Instituto de Salud Carlos III for her predoctoral fellowship (IFI21/00008) . We thank electron microscopy service of UPV for their support. R.M.M. thanks to the European Union's Horizon EUROPE research and innovation programme under grant agreement No 101093042. E. C. thanks the Instituto de Salud Carlos III for funding the proyects Miguel Servet 2023 CP23/00086 and PI24_01239, both co-funded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Anthracene-Modified Nanoporous Silica Nanoparticles for ATP Detection and Salivary Diagnostics in Parkinson&apos, s Disease

  • Ahi, E.E.
  • Climent Terol, Estela
  • Beyret, Cansu
  • Caglayan, Mehmet Gokhan
  • Coban, Burak
  • Yilmaz, Rezzak
  • Durmus, Mahmut
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] ATP is an essential biological molecule, and abnormal levels are linked to various diseases. In this study, we developed an optical sensor array consisting of an anthracene-modified MCM-41 mesoporous nanoparticle-based hybrid organic-inorganic material to detect ATP in a TRIS-HCl buffer (pH 7). To create the sensor, we synthesized MCM-41 silica nanoparticles and functionalized them with aminoanthracene and imidazolium-anthracene groups. The fluorescence responses of the optical sensor array were recorded and analyzed by using a pattern recognition protocol, specifically linear discriminant analysis, to distinguish between ATP, ADP, AMP, and potential interferents. Quantitative regression analysis of ATP in TRIS-HCl was performed using artificial neural networks, which yielded an acceptable error rate of 7.8%. The sensor array was also evaluated for discrimination of Parkinson's disease (PD) from healthy controls, based on pattern recognition of ATP-related analytes in saliva samples from 24 patients with PD and 23 healthy controls. The results showed that the MCM-41 mesoporous silica nanoparticle-based sensor array can discriminate PD by pattern recognition with 73.7% sensitivity and 83.3% specificity., The diagnostic part of this study is supported by the Ankara University Scientific Research Projects Coordination Office (TSA-2023-2648 and TSA-2025-3825). V.M.-C. acknowledges financial support from the Project CIDEGENT/2020/031 funded by the Generalitat Valenciana, Project ESGENT/2024/ 001 funded by the Generalitat Valenciana, project PID2024- 157188OB-I00 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, project PID2020-113256RA-I00 funded by MICIU/AEI/10.13039/ 501100011033, and project CNS2023-144879 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. R.M.-M. acknowledges the European Union s Horizon EUROPE research and innovation program under grant agreement no. 101093042, project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, project PID2021-126304OB-C41 funded by MICIU/AEI/10.13039/ 501100011033 and FEDER A way to make Europe, and project PROMETEO CIPROM/2021/007 funded by Generalitat Valenciana. E.C. thanks the Instituto de Salud Carlos III for founding the projects Miguel Servet 2023 CP23/00086 and PI24_01239, both cofunded by the European Union.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Overcoming Antifungal Resistance: A Histatin 5-Gated Nanodevice for On-Demand Surfactant Delivery against Infections

  • Reyes-Torres, Miguel|||0000-0003-4751-2698
  • Hicke-García, Francisco Javier|||0000-0002-8419-0467
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Sanz-Álvarez, Víctor|||0009-0004-7967-6552
  • Martínez-Bisbal, M.Carmen|||0000-0002-8526-4413
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • de Boer, Leonie
  • Zaat, Sebastian A. J.
  • Diez-Sánchez, Paula
[EN] The escalating incidence of fungal infections, coupled with the emergence of antifungal resistance, represents a formidable global public health challenge. is a common opportunistic fungus that causes life-threatening, widespread candidiasis, especially in immunocompromised patients. Conventional antifungals, including azoles, echinocandins, and polyenes, have some drawbacks, such as host toxicity and the rapid appearance of resistant fungal strains. To overcome these limitations, we engineered a stimuli-responsive gated antimicrobial nanoparticle using mesoporous silica nanoparticles, functionalized with the antimicrobial peptide histatin 5 (Hst5) and loaded with the surfactant (3-(methyl)-1-tetradecylimidazolium) [C14MIM]+. The nanoparticles exhibit potent antimicrobial activity against , with minimum inhibitory concentration values comparable to current clinical antifungals. Crucially, the nanodevice exhibits a dual mechanism of action, causing membrane disruption and inducing reactive oxygen species generation, which effectively hinders the development of resistance. Furthermore, the nanoparticles display strong synergistic interactions with conventional antifungals, significantly enhancing their efficacy. In addition to its planktonic activity, the system effectively inhibits biofilm formation and demonstrates high biocompatibility with human dermal cell lines. Based on these results, the nanodevice is successfully incorporated into a wound dressing matrix, demonstrating its promising translational potential for the topical treatment of cutaneous candidiasis., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, PID2024-155683OB-C41, and PID2024-162542OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund-a way of funding Europe. This work was also supported by the European Research Council (ERC) via Advanced Grant (101,052,997, EDISON). This study formed part of the Advanced Materials program (MFA/2022/053) and the AGROALNEXT program (AGROALNEXT/2022/032), supported by MCIN with funding from the European Union NextGenerationEU (PRTR-C17 & centerdot;I1) and by Generalitat Valenciana. The study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER, Consorcio Centro de Investigacion Biomedica en Red (CB06/01/2012). M.R.-T. thanks MIU for his FPU grant (FPU21/03142). F.J.H. thanks Ministerio de Universidades (MIU, Spanish Government) for his FPU grant (FPU20/06021). P.D. thanks the Instituto de Salud Carlos III and the European Social Fund for financial support "Miguel Servet" (CP24/00043).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Iridium Nanoparticle-Gated Janus Nanomachines for Enzyme-Controlled Drug Delivery

  • Mayol, Beatriz
  • Gonzalez-Jimenez, Marta
  • Sanchez, Alfredo
  • Portela, Susana
  • Pradana-López, Sandra
  • Moreno, Teresa
  • Cai, RuiYuan
  • Martinez-Ruiz, Paloma
  • Martinez-Quiles, Narcisa
  • Diez-Sánchez, Paula
  • Ojeda, Irene
  • Vilela, Diana
  • Villalonga, Reynaldo
  • López-Benet, Carolina
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Controlled drug delivery systems (DDSs) have emerged as a promising alternative to conventional therapies, aiming to optimize drug release profiles and improve therapeutic outcomes while reducing systemic side effects. In this work, iridium-gated Janus nanomachines are proposed as enzyme-regulated platforms for smart and autonomous drug delivery. These hybrid nanostructures consist of mesoporous silica nanoparticles asymmetrically functionalized with gold nanoparticles bearing surface-anchored enzymes on the metallic hemisphere, while the opposite mesoporous face incorporates pH-responsive molecular gates based on aminophenylboronic acid and d-lactose-functionalized iridium nanoparticles, enabling efficient cargo loading and motility behavior. To evaluate nanomachine operation, two enzymatic systems were employed: glucose oxidase (GOx) and a tandem esterase/alcohol oxidase (AOX) system, using spectrophotometric monitoring of the model cargo release. Both platforms exhibited well-defined release kinetics and good correlation between substrate concentration and high selectivity toward their respective inputs. Motility studies revealed the appearance of two particle populations in the presence of glucose or methanol, consistent with enhanced motion driven by catalytic reactions at the iridium nanoparticle surface upon enzymatic hydrogen peroxide generation. Finally, the GOx-based nanomachine loaded with the antitumoral drug doxorubicin (DOXO) demonstrated efficient cellular internalization, preserved biocompatibility, and enhanced antitumoral activity in HeLa cells. Overall, this work reinforces the potential of enzyme-controlled Janus nanomachines as multifunctional platforms integrating autonomous motion and stimulus-responsive drug delivery for advanced therapeutic applications., Financial support from the Spanish Ministry of Economy and Competitiveness (projects CTQ2017-87954-P and PID2021-125723NB-I00), the Spanish Ministry of Science and Innovation (projects CNS2022-135255 and PID2024-155683OB-C41), and the European Research Council (ERC) via Advanced Grant (101052997, EDISON) is gratefully acknowledged. I.O. thanks the financial support from the regional government of Madrid and Complutense University (PR17/24-31938). M.G. also thanks the Public Employment Service (SEPE) and NextGenerationEU funds for financial support through the Investigo Program (CT19/23-INVM-56) and the Community of Madrid and the European Social Fund Plus (ESF+) CT3/25/PEJ-2024-AI/BIO-32377. T.M. also thanks the Spanish Ministry of Education, Vocational Training and Sports for the Collaboration Grant BDNS-764344. P.D. and S.P.-L. thank the Instituto de Salud Carlos III and the European Social Fund for financial support "Miguel Servet" (CP24/00043) and "Sara Borrell" (CD24/00075), respectively. C.L-B also thanks UPV for her predoctoral grant (PAID-01-25).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Test Strips Based on Gated Nanoporous Anodic Alumina for the Rapid and Accurate Detection of Pseudomonas aeruginosa in Clinical Samples

  • Torres-Mesado, Andrea
  • Patricia Bernabé-Quispe
  • Tormo-Mas, María Ángeles
  • Pemán, Javier
  • Climent Terol, Estela
  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Pseudomonas aeruginosa is a high-priority pathogen responsible for up to 23% of infections in intensive care units, yet current diagnostic methods remain hindered by multiday delays or high technical complexity. In this study, we report a rapid and highly sensitive biosensor based on nanoporous anodic alumina (NAA) capped with a specific oligonucleotide molecular gate targeting the phzA2 gene. The S3 biosensor achieved a limit of detection (LOD) of 0.153 ng mu L-1 for genomic DNA and an exceptional 28 CFU mL(-1) for direct bacterial detection without the need for prior DNA extraction. Validation in 63 clinical urine samples demonstrated a sensitivity of 91.67% and a specificity of 94.87% (AUC: 0.961, p-value < 0.0001). Furthermore, the sensor was integrated into Lateral Flow Assay (LFA), enabling the discrimination of positive and negative clinical samples in only 1 min with 100% specificity and 90.9% sensitivity. These results, combined with a one-year stability at 4 degrees C, position this gated-nanodevice as a robust and low-cost tool for Point-of-care (POC) diagnosis of P. aeruginosa infections., This research was funded by projects PID2024-155683OB-C41, PID2021-126304OB-C41, PID2021-122875OB-I00, and TED2021-132114B-100, supported by MCIN/AEI/10.13039/501100011033, the European Regional Development Fund, the European Union (NextGenerationEU/PRTR), and the Generalitat Valenciana (CIPROM/2021/007). This study is part of the Advanced Materials programme (MFA/2022/053) and was supported by MCIN with funding from the European Union's NextGenerationEU (PRTR-C17. I1) and by the Generalitat Valenciana. The project was also funded by Ayuntamiento de Valencia (SPI2024-096) and Instituto de Salud Carlos III (PI24/01239), cofunded by the European Union. In the same way, A.T. would like to thank the INVESTIGO program of the Ministry of Innovation, Universities, Research, and Digital Society of the Valencian Community for offering this research opportunity (INVEST/2023/443). To conclude, A.T. is grateful to the Asociacion Espanola Contra el Cancer for her 2024 predoctoral fellowship (PRDVA246577TORR (2024-0590-1)), which enabled this research. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086), cofounded by the European Union. The authors thank Electron Microscopy Service at UPV for support. Funding for open access charge: CRUE-Universitat Politecnica de Valencia.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Preserving Heritage Spaces by a Tea Tree Oil-Loaded Silica Microparticles System for Air Purification

  • Tassi, Anna Laura
  • Cebriá-Mendoza, María Concepción
  • Pinna, Daniela
  • Santiglia, Alessia
  • Santagostini, Laura
  • Guglielmi, Vittoria
  • Bosch-Roig, Pilar|||0000-0003-2019-399X
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Featured Application This research aims to develop a cost-effective and easy-to-use technology for improving indoor air quality through the reduction of fungal and bacterial contamination. While the primary objective of the project is the conservation of cultural heritage, the proposed tool also has broader applications as a passive air purification system for residential and occupational settings, contributing to healthier indoor environments by lowering harmful microbial loads.Abstract Airborne fungi and bacteria pose a severe challenge for conservators, as they can settle on artistic surfaces, leading to chemical, physical and aesthetic degradation of artworks. A new air-cleaning system has been developed to reduce indoor airborne microorganisms by leveraging the antimicrobial potential of Tea Tree (Melaleuca alternifolia) Essential Oil (TTEO) encapsulated within the pores of MCM-41 mesoporous silica microparticles (MCM-TTEO), thereby extending its antimicrobial activity and enhancing its efficacy. Experimental data showed a progressive release of TTEO from the MCM-TTEO system during the 5 weeks monitoring. The release rate was quite linear in the first week, reaching about 16.2%, before plateauing at approximately 30% in the next weeks. A comparison of the performances of the MCM-TTEO system with those of the non-encapsulated ('free') TTEO was performed using a comprehensive air quality monitoring approach, which tracked temperature, relative humidity, microbial loads and particulate matter. Results demonstrate that the MCM-TTEO system maintained higher biocidal activity over the 5-week study period than the free EO. Furthermore, the biocidal efficacy increased when the MCM-TTEO system was used in direct contact with microorganisms. These promising findings highlight the potential for exploring different combinations of the two components in both passive and active configurations, including the development of air filtration systems., Erasmus + Placement 2023/2024 Scholarship funded A.L.T. staying in Valencia and the Santos Juanes Project funds the lab fungible material. This research was funded by the Spanish Government (projects PID2021-126304OB-C41, PID2021-128141OB-C22, PID2024-155683OB-C41 and PID2024-162542OB-I00), MCUI/FEDER, EU and CIBER-Consorcio Centro de Investigacion Biomedica en Red (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion and the Generalitat Valenciana (CIPROM/2021/007).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A Fluorogenic Biosensor for Direct Detection of Vibrio vulnificus, a Climate Change Biomarker

  • Aranda-Sobrino, María Nieves
  • Carmona-Salido, Héctor
  • Sanjuán, Eva
  • Amaro, Carmen
  • Caballos-Gómez, María Isabel
  • López-Palacios, Alba|||0000-0002-4397-277X
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
[EN] Vibrio vulnificus, a marine pathogen and climate change biomarker, poses serious risks to human and animal health through seafood consumption and seawater exposure. Rapid detection methods are urgently needed for both vibriosis diagnosis and surveillance in warming coastal waters. We report a fluorogenic biosensor based on nanoporous anodic alumina loaded with rhodamine B and capped with an oligonucleotide probe targeting a unique sequence of the vvhA cytolysin gene, specific to V. vulnificus. In the presence of the target DNA, the probe is displaced, pores open, and the fluorophore is released, generating a measurable signal. The biosensor exhibited high sensitivity and selectivity across diverse matrices, including fish mucus and serum, human serum, sterilized brackish water, and-critically-unprocessed natural lake and seawater samples, without DNA extraction or amplification. Detection limits ranged between 10 & sup2; and 5 & times; 10 & sup2; CFU mL(-)& sup1;, comparable in sensitivity to state-of-the-art qPCR assays. The biosensor outperformed conventional approaches in speed, simplicity, and cost-effectiveness, while maintaining accuracy. These findings underscore the potential of this platform for integrated One Health applications, bridging environmental monitoring with rapid diagnosis of vibriosis in humans and animals.Preliminary results from this study were previously made available as a preprint in SSRN (DOI: https://ssrn.com/abstract=5032822)., Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Agencia Estatal de Investigación (AEI/10.13039/501100011033), with co&#8208; funding from the European Regional Development Fund (ERDF), European Union, Grant/Award Numbers: PID2020&#8208;120619RB&#8208;I00, PID2024&#8208;162627OB&#8208;I00, PID2021&#8208;126304OB&#8208;C41, PID2024&#8208;155683OB&#8208;C41; Generalitat Valenciana (Spain), Grant/Award Numbers: CIAICO/2021/293, CIAICO/2024/236; Spanish Ministry of Science and Innovation (MCIN) with funding from the European Union European Union NextGenerationEU (PRTR&#8208;C17.I1) and the Generalitat Valenciana (GVA&#8208;THINKINAZUL/2021/027; Principal Investigators: Carmen Amaro and B. Fouz, Universitat de València); Instituto de Salud Carlos III, Grant/Award Number: CIBER ConsorcioCentrodeInvestigaciónBiomédicaenRed(CB06/01/2012)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Molecular Cages as Probes in Indicator Displacement Assays: The Case of Scopolamine Detection

  • Montà-González, Giovanni|||0000-0002-0739-9937
  • Garrido-García, Eva María
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Climent Terol, Estela
  • Vicent, Cristian
[EN] A study of the Pd-based molecular cage C1 host-guest properties against fluorescein and the drug scopolamine is reported. C1 forms an interpenetrated structure C12 in the presence of >= 40% water in H2O/DMSO solvent mixtures. The presence of fluorescein (FL) induces the disassembly of the C12 structure to form the [FL2 subset of C1] complex. Moreover, the addition of scopolamine (SCOP, a drug typically involved in drug-facilitated sexual assaults) to [FL2 subset of C1] results in fluorescein release and the formation of [SCOP subset of C12], obtaining a fluorescence signal proportional to the concentration of scopolamine with a limit of detection as low as 59.4 mu g mL-1. A good selectivity for scopolamine against other drugs such as MDMA, cocaine, GBL, and ketamine is observed. This is the first scopolamine detection method described to date using a molecular cage and one of the very few examples of the use of cages in indicator displacement assays. Similar concepts could be applied to the design of other molecular cage-based sensors for the detection of target analytes., V.M.-C. acknowledges the financial support from projects ESGENT/2024/001 and CIDEGENT/2020/031, both funded by the Generalitat Valenciana, Project PID2024-157188OB-I00 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, Project PID2020-113256RA-I00 funded by MICIU/AEI/10.13039/501100011033, and Project CNS2023-144879 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. R.M.- M. acknowledges the financial support from Project PROMETEO CIPROM/2021/007 from the Generalitat Valenciana, project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, and project PID2021-126304OB-C41 funded by MICIU/AEI/10.13039/501100011033/and FEDER A way to make Europe. This research was supported by CIBER Consorcio Centro de Investigacion Biomedica en Red (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) and E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would like to acknowledge the Rigel computing system of the Universitat Politecnica de Valencia for providing the computational resources necessary for this study. The authors thank the U26 facility of ICTS "NANBIOSIS" and the nuclear magnetic resonance facility of Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe (CIPF) for NMR experiments. The authors thank "Servei Central d'Instrumentacio Cientifica (SCIC)" at Universitat Jaume I for mass spectrometry measurements.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Chitosan nanoparticles-encapsulated cannabis extracts and their antimicrobial potential against skin pathogens

  • Skala, Tomas
  • Frankova, Adela
  • Tauchen, Jan
  • Kahankova, Zdenka
  • Hubka, Vít
  • Kloucek, Pavel
  • Ventura-Cobos, Jordi|||0000-0001-8475-9820
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • Llopis-Lorente, Antoni|||0000-0002-6987-9506
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
[EN] Cannabis compounds are well-known for their therapeutic applications in the treatment of various health issues. These substances, mainly cannabinoids, are known for their antimicrobial properties and ability to interact with various cells through endocannabinoid receptors. However, the limitations of cannabis extract, particularly its viscosity, stickiness, and low bioavailability when applied topically, limit its use in dermatology. To enhance topical applications for treating bacterial infections and dermatophytosis, cannabis extracts were encapsulated in chitosan nanoparticles, an easily accessible and cost-effective. Cannabis extracts were prepared from three cannabis strains differing in content of major cannabinoids, namely Chocolope (THCA-A), Jonas 1 (CBDA), and Hemp G (CBGA), and subsequently were encapsulated in chitosan nanoparticles. The resulting particles were characterized, and antimicrobial and cytotoxic activity was evaluated. The mean size of particles ranged from 89.1 +/- 24.8 nm for empty nanoparticles to 355.6 +/- 101.6 nm for particles containing Hemp G extract. Considering the extract:chitosan ratio (1:10 w/w, 1:20 w/w respectively) and the encapsulation efficiency (EE) range from 44.65 +/- 4.39% to 94.44 +/- 0.93%, total amount of extracts encapsulated in chitosan nanoparticles ranged from 2.96 +/- 0.05 to 5.61 +/- 0.19% in 1 g of chitosan nanopowder. Most significant antimicrobial effect was observed against the fungi Nannizzia fulva CCF 6025, where the MIC80 of the pure extract from Jonas 1 variety was 256 mu g/mL while the encapsulated extract in chitosan nanoparticles (1:10 w/w extract:chitosan ratio) inhibited growth at a concentration of 256 mu g/mL of nanoparticles (corresponding to 13.05 +/- 0.13 mu g/mL of extract). Overall, encapsulation reduced the amount of extract required to inhibit the growth of pathogenic microorganisms by up to several times, notably in case of dermatophytes, compared to non-encapsulated extracts. Encapsulation also reduced the cytotoxic effects of the extracts on human keratinocytes. Furthermore, pure high-THCA-A extract and encapsulated extract in chitosan nanoparticles slightly increased cell viability after 72 h exposure in low concentrations compared to control. These results may suggest the chitosan nanoparticles-encapsulated formulations as a suitable topical delivery form of cannabis extracts, offering a possible adjunctive treatment of dermatophytosis and wound healing., The author(s) declare that financial support was received for the research and/or publication of this article. The work used facilities provided by the METROFOOD-CZ Research Infrastructure (https://metrofood.cz), supported by the Ministry of Education, Youth and Sports of the Czech Republic (Project No. LM2023064). This research was supported by SGS project No. SV23-18-21310 and TACR Sigma -DC2 TQ03000678. The authors would like to acknowledge the support from the Spanish Ministry of Science and Innovation, AEI, and FEDER-EU (projects PID2021-128141OB-C22 and PID2021-126304OB-C41). AM-A thanks the Universitat Politecnica de Valencia (UPV) for her Ph.D. grant (DOCEMPR22). AL-L thanks the Spanish Government for his "Ramon y Cajal" Fellowship (RYC2021-034728-I).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Smartphone-assisted lateral flow nanosensor for the selective detection of GHB in urine

  • Garrido-García, Eva María
  • Hernández-Sigüenza, Guillermo|||0000-0002-2075-3005
  • Mollá-Guerola, Lara|||0009-0009-2387-9816
  • López-Lima, Rocío|||0009-0007-8121-8085
  • Ortiz-Gómez, Eduardo|||0009-0005-5778-9158
  • Montà-González, Giovanni|||0000-0002-0739-9937
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Climent Terol, Estela
  • Gaviña, Pablo
[EN] We report a rapid test strip based on mesoporous silica nanoparticles functionalized with a specific GABA(B) receptor agonist to selectively detect gamma-hydroxybutyric acid (GHB) in urine samples. The sensing mechanism involves rhodamine B-loaded MCM-41 silica nanoparticles whose pores are capped with a GABA-derived ligand (baclofen) acting as a gatekeeper via supramolecular interactions with the GABA(B) receptor protein. In the presence of GHB, competitive binding produces GABA(B) receptor protein displacement, leading to pore opening and fluorophore release, which is detected via fluorescence readout. The nanosensor demonstrated high sensitivity, with a limit of detection (LOD) of 168 mu M in buffer solution and 41 mu M in diluted urine. Selectivity assays showed highly specific sensor response over common drugs such as cocaine, morphine, MDMA, heroin, scopolamine, 1,4-butenediol (1,4-BD), gamma-aminobutyric acid (GABA), and gamma-butyrolactone (GBL). The sensing material was also incorporated into a lateral flow assay (LFA) platform with a smartphone-assisted fluorescence readout, providing a rapid, portable, and low-cost analysis of GHB. The resulting test strip exhibited high sensitivity, with a LOD of 0.28 mu M in diluted urine, which is low enough to clearly distinguish between physiological endogenous GHB levels (similar to 96 mu M) and exogenous intake within only 1 min, a crucial requirement in forensic and clinical toxicology. This portable, cost-effective method holds strong potential for on-site forensic and clinical GHB screening., This work was financially supported by the Universitat Politecnica de Valencia (PAID-06-23) and by the Spanish Ministry of Science and Innovation through projects PID2021-126304OB-C41 and PID2024-155683OB-C41 (MICIU/AEI/10.13039/501100011033), co-funded by the European Regional Development Fund (FEDER, "A Way of Making Europe"). This study also forms part of the Advanced Materials Program (MFA/2022/053) and was supported by MCIN with funding from the European Union-Next Generation EU (PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). E. G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant(UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer

  • Lameirinhas, Ana
  • Diez-Sánchez, Paula
  • Ágreda-Roca, Anna
  • Torres-Ruiz, Sandra
  • Sánchez-Serrano, Paloma
  • Tapia, Marta
  • Lluch, Ana
  • Bermejo, Begoña
  • Cejalvo, Juan Miguel
  • Eroles, Pilar
  • Garrido-Cano, Iris
  • Hicke-García, Francisco Javier|||0000-0002-8419-0467
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Triple-negative breast cancer (TNBC) remains a highly aggressive subtype with limited treatment options and poor prognosis. While most therapies target tumor cells, the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), plays a key role in tumor progression, therapy resistance, and immune suppression.We developed NP-FAP-DOX, a mesoporous silica nanoparticle-based nanodevice loaded with doxorubicin and functionalized with a fibroblast activation protein alpha (FAP-alpha) ligand peptide for selective binding to FAP-alpha-positive CAFs. FAP-alpha targeting ability and cytotoxic effect were assessed in TNBC cells, patient-derived CAFs, and patient-derived organoids (PDOs). In vivo efficacy was evaluated in the murine orthotopic TNBC 4T1 allograft model, assessing tumor growth inhibition, toxicity, CAFs depletion, extracellular matrix degradation, apoptosis induction, and TME-associated cellular and stromal changes. NP-FAP-DOX exhibited controlled drug release, selective binding to FAP-alpha, and cytotoxicity in TNBC cells, patient-derived CAFs, and PDOs. In vivo, NP-FAP-DOX reduced tumor growth, depleted CAFs, degraded the extracellular matrix, induced apoptosis, increased lymphocyte infiltration, and decreased M2-like macrophages. Compared with free doxorubicin, NP-FAP-DOX enhanced therapeutic efficacy while reducing cardiotoxicity and systemic side effects. These findings highlight NP-FAP-DOX as a promising nanomedicine strategy for TNBC, integrating tumor inhibition, TME remodeling, and immune activation, with strong potential for clinical translation., This work was supported by the Spanish Government and cofinanced by FEDER Funds (AES Program, grants PI21/01351; CIBERONC, Biomedical Research Networking Centre for Cancer CB16/12/00481), by projects PID2021-126304OB-C41 and PID2024-155683OB-C41 from MCIN/AEI /10.13039/501100011033/ and FEDER-A way of doing Europe, and also by Universitat Politecnica de Valencia (PAID-06-23, Primeros Proyectos de Investigacion). The authors are also grateful for the Advanced Materials program (MFA/2022/049) supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Project CIPROM/2021/007 from Generalitat Valenciana and CIBER-BBN, Biomedical Research Networking Centre for Bioengineering, Biomaterials and Nanomedicine (CB06/01/2012). A.L. and A.A.-R. were funded by predoctoral grants from the Scientific Foundation of the Spanish Association Against Cancer. P.D. was also funded by a postdoctoral grant from the Scientific Foundation of the Spanish Association Against Cancer (INVES246470DIEZ). F.J.H. was funded by Ministerio de Universidades (FPU20/06021). S.T.-R. was funded by Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (ACIF/2019/119). I.G.-C. was funded by Margarita Salas postdoctoral grant (European Union-Next generation EU). M.T. and J.M.C. were funded by Sociedad Espanola de Oncologia Medica (Rio Hortega-SEOM). The funders had no role in the study design, data collection, analysis, interpretation, or manuscript preparation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

In Vivo Study of Osseointegrable Bone Calcium Phosphate (CaP) Implants Coated with a Vanillin Derivative

  • Medaglia, Serena|||0000-0003-3537-9842
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Marcos Martínez, María Dolores|||0000-0001-7079-8589
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Bernabe-Quispe, Patricia
  • Tomás-Chenoll, Julia
  • Cebriá-Mendoza, María Concepción
  • Tormo-Mas, Maria Angeles
  • Primo Capella, Victor
  • Peris-Serra, José-Luis
[EN] Background/Objectives: Orthopaedic infections associated with implant surgery remain a major public health concern, often caused by bacterial colonization of implant surfaces. Staphylococcus epidermidis is among the most common pathogens involved. Developing antimicrobial bone implants that prevent infection without compromising bone regeneration is therefore essential. This study investigates the antimicrobial and osteointegrative performance of calcium phosphate (CaP) materials functionalized with vanillin, an essential oil component with known antimicrobial properties. Methods: Commercial CaP regenerative materials were covalently coated with vanillin. Antibacterial activity was evaluated against Staphylococcus epidermidis RP62A using viability assays. In vivo osseointegration was assessed in New Zealand female rabbits implanted with vanillin-coated and uncoated CaP scaffolds. Results: Vanillin-functionalized CaP scaffolds exhibited strong bactericidal activity at 24 h and bacteriostatic effects at 48 h at a concentration of 10 mg/mL. In vivo analyses showed no significant differences in osseointegration between vanillin-coated implants and control CaP materials. Conclusions: Vanillin-functionalized CaP materials maintain a high safety profile without impairing bone integration, supporting their potential use in clinical applications., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, PID2021-122875OB-100, PID2024-155683OB-C41 and PID2024-162542OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund-a way of funding Europe. Also, this study forms part of the Advanced Materials programme (MFA/2022/053) and was supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1) and by Generalitat Valenciana. The study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB06/01/2012) and MICRO-STOP project, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. All figures done with BioRender.com. S.M. thanks the Generalitat Valenciana for her Grisolia fellowship (GRISOLIAP/2018/149). M.C-M thanks the Generalitat Valenciana for the postdoctoral contract (INVEST/2022/381). Part of the equipment used to develop this work was supported by Generalitat Valenciana (IDIFEDER/2021/044) and is susceptible to be co-founded through the Operational Programme of the European Regional Development Fund. The authors also thank the Electron Microscopy Service at UPV for support.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Remodeling the tumor immune microenvironment with lipid nanoparticles

  • Martínez-Latorre, Javier|||0000-0001-5421-5371
[ES] Esta tesis doctoral, titulada "Remodelación del microambiente inmunitario tumoral con nanopartículas lipídicas", explora el desarrollo de nuevas estrategias inmunoterapéuticas contra el cáncer, tanto a nivel terapéutico como de métodos de administración. En concreto, el trabajo investiga enfoques alternativos y relativamente poco explorados, como las inmunoterapias basadas en macrófagos y la inmunoterapia mediada por antígenos exógenos, que tratan de superar las principales limitaciones de las modalidades inmunoterapéuticas actuales. Paralelamente, la tesis evalúa las nanopartículas lipídicas (LNP) como sistemas de administración de genes no virales para la inmunoterapia. El primer capítulo experimental describe el desarrollo de una novedosa plataforma LNP para la inmunoterapia basada en macrófagos. Las LNP cargadas con ADN plasmídico o ARNm de luciferasa se funcionalizaron con ácido fólico (FA) para dirigirse a las células cancerosas pancreáticas que expresan el receptor de folato y con un anticuerpo anti-CD47 (aCD47) para bloquear la evasión inmunitaria mediada por CD47. Los resultados demuestran una transfección eficaz de las células de cáncer de páncreas, con las LNP cargadas con ARNm superando a las formulaciones basadas en plásmidos. Además, la funcionalización con FA mejoró la captación dirigida de LNP in vitro y la funcionalización con aCD47 restauró la fagocitosis de las células tumorales por los macrófagos in vitro. Los experimentos in vivo en modelos de xenoinjertos Capan-2 de ratón con LNP-ARNm-FA-aCD47 demostraron la expresión in vivo de luciferasa y promovieron un cambio hacia un fenotipo de macrófagos proinflamatorio M1 dentro del microambiente tumoral. En conjunto, estos resultados presentan una plataforma LNP optimizada, capaz de inmunomodular los macrófagos asociados a tumores. El segundo capítulo experimental presenta una novedosa inmunoterapia mediada por antígenos exógenos basada en el epítopo alpha-Gal (galactosa-alpha-1,3-galactosa). El epítopo alpha-Gal es altamente inmunogénico en humanos y provoca fuertes respuestas debido a anticuerpos preexistentes. Se desarrollaron LNP que codifican el ARNm de la alpha-1,3-galactosiltransferasa (alpha-GT) para permitir la biosíntesis endógena de alpha-Gal en la superficie de las células tumorales. El tratamiento con estas LNP indujo con éxito la expresión de alpha-Gal en líneas celulares cancerosas murinas y humanas y promovió el reclutamiento de anticuerpos anti-alpha-Gal humanos naturales hacia las células tumorales. Estos resultados identifican a la LNP alpha como una plataforma inmunoterapéutica prometedora que aprovecha la inmunidad humoral preexistente. El tercer capítulo experimental describe una novedosa inmunoterapia mediada por antígenos exógenos basada en la proteína hemaglutinina (H) del virus del sarampión. La proteína H es un antígeno altamente inmunogénico en humanos debido a la vacunación generalizada contra el virus del sarampión. Se formularon LNP que codifican la proteína H y se demostró que transfectan eficazmente tanto cultivos celulares cancerosos bidimensionales como esferoides tumorales tridimensionales. Además, la administración in vivo de LNP H en ratones vacunados contra el sarampión con tumores de melanoma B16-BL6 dio lugar a una disminución significativa del crecimiento tumoral. Este efecto terapéutico está asociado con una fuerte infiltración intratumoral de linfocitos T citotóxicos CD8+, un cambio en la proporción de células T CD8/CD4 y la producción ex vivo de citocinas proinflamatorias tras la reactivación del antígeno, características distintivas de una potente respuesta inmunitaria mediada por células T CD8+. En conjunto, estos resultados ponen de relieve el potencial de LNP H como nueva estrategia para mejorar la inmunogenicidad tumoral y provocar fuertes respuestas inmunitarias antitumorales., [EN] This doctoral thesis, entitled "Remodeling the Tumor Immune Microenvironment with Lipid Nanoparticles", explores the development of novel cancer immunotherapeutic strategies at both the therapeutic and delivery levels. Specifically, the work investigates alternative and comparatively underexplored approaches, including macrophage-based immunotherapies and exogenous antigen-mediated immunotherapy, which seek to overcome key limitations of current immunotherapeutic modalities. In parallel, the thesis evaluates lipid nanoparticles (LNPs) as non-viral gene delivery systems for immunotherapy. The first experimental chapter describes the development of a novel LNP platform for macrophage-based immunotherapy. LNPs loaded with either luciferase-encoding plasmid DNA or mRNA were functionalized with folic acid (FA) for targeting folate receptor-expressing pancreatic cancer cells and with an anti-CD47 antibody (aCD47) to block CD47-mediated immune evasion. The results demonstrate efficient transfection of pancreatic cancer cells, with mRNA-loaded LNPs outperforming plasmid-based formulations. Moreover, the functionalization with FA enhanced targeted uptake of LNPs in vitro and aCD47 functionalization restored the phagocytosis of tumor cells by macrophages in vitro. In vivo experiments in mouse Capan-2 xenograft models with LNP-mRNA-FA-aCD47 demonstrated in vivo expression of luciferase and promoted a shift to a pro-inflammatory, M1-like macrophage phenotype within the tumor microenvironment. Together, these results present an optimized LNP platform capable of immunomodulating tumor-associated macrophages. The second experimental chapter presents a novel exogenous antigen-mediated immunotherapy based on the alpha-Gal epitope (galactose-alpha-1,3-galactose). alpha-Gal epitope is highly immunogenic in humans and elicits strong pre-existing antibody responses. LNPs encoding alpha-1,3-galactosyltransferase (alpha-GT) mRNA were developed to enable endogenous alpha-Gal biosynthesis on tumor cell surfaces. Treatment with these LNPs successfully induced alpha-Gal expression in both murine and human cancer cell lines and promoted the recruitment of naturally occurring human anti-alpha-Gal antibodies to tumor cells. These results identify LNP alpha as a promising immunotherapeutic platform that exploits pre-existing humoral immunity. The third experimental chapter describes a novel exogenous antigen-mediated immunotherapy based on the hemagglutinin (H) protein of the measles virus. H protein is a highly immunogenic antigen in humans due to widespread vaccination against measles virus. LNPs encoding H protein were formulated and shown to efficiently transfect both two-dimensional cancer cell cultures and three-dimensional tumor spheroids. Moreover, in vivo administration of H-expressing LNPs in measles-vaccinated mice bearing B16-BL6 melanoma tumors resulted in significant tumor growth delay. This therapeutic effect is associated with robust intratumoral infiltration of CD8+ cytotoxic T lymphocytes, a shift in the CD8/CD4 T cell ratio, and ex vivo production of pro-inflammatory cytokines upon antigen recall, hallmarks of a potent CD8+ T cell-mediated immune response. Together, these results highlight the potential of LNP H as a novel strategy to enhance tumor immunogenicity and elicit strong antitumor immune responses. We hope that the results obtained in this doctoral thesis will demonstrate the versatility of LNP-based platforms and support the development of innovative cancer immunotherapies that leverage alternative immunotherapeutic strategies, such as macrophage-based approaches and exogenous antigen-mediated immunotherapy., [CA] Esta tesi doctoral, titulada «Remodelació del microambient immunitari tumoral amb nanopartícules lipídiques», explora el desenvolupament de noves estratègies immunoterapèutiques contra el càncer, tant a nivell terapèutic com de mètodes d'administració. En concret, el treball investiga enfocaments alternatius i relativament poc explorats, com les immunoteràpies basades en macròfags i la immunoteràpia mediada per antígens exògens, que tracten de superar les principals limitacions de les modalitats immunoterapèutiques actuals. Paral·lelament, la tesi avalua les nanopartícules lipídiques (LNP) com a sistemes d'administració de gens no virals per a la immunoteràpia. El primer capítol experimental descriu el desenvolupament d'una nova plataforma LNP per a la immunoteràpia basada en macròfags. Les LNP carregades amb ADN plasmídic o ARNm de luciferasa es van funcionalitzar amb àcid fòlic (FA) per a dirigir-se a les cèl·lules canceroses pancreàtiques que expressen el receptor de folat i amb un anticòs anti-CD47 (aCD47) per a bloquejar l'evasió immunitària mediada per CD47. Els resultats demostren una transfecció eficaç de les cèl·lules de càncer de pàncrees, amb les LNP carregades amb ARNm superant a les formulacions basades en plasmidis. A més, la funcionalització amb FA va millorar la captació dirigida de LNP in vitro i la funcionalització amb aCD47 va restaurar la fagocitosi de les cèl·lules tumorals pels macròfags in vitro. Els experiments in vivo en models de xenotrasplantament Capan-2 de ratolí amb LNP-ARNm-FA-aCD47 van demostrar l'expressió in vivo de luciferasa i van promoure un canvi cap a un fenotip de macròfags proinflamatori M1 dins del microambient tumoral. En conjunt, aquests resultats presenten una plataforma LNP optimitzada, capaç de immunomodular els macròfags associats a tumors. El segon capítol experimental presenta una nova immunoteràpia mediada per antígens exògens basada en el epítop alpha-Gal (galactosa-¿-1,3-galactosa). El epítop alpha-Gal és altament immunogènic en humans i provoca fortes respostes a causa d'anticossos preexistents. Es van desenvolupar LNP que codifiquen el ARNm de la ¿-1,3-galactosiltransferasa (¿-GT) per a permetre la biosíntesi endògena de ¿-Gal en la superfície de les cèl·lules tumorals. El tractament amb estes LNP va induir amb èxit l'expressió de ¿-Gal en línies cel·lulars canceroses murines i humanes i va promoure el reclutament d'anticossos anti-¿-Gal humans naturals cap a les cèl·lules tumorals. Estos resultats identifiquen a la LNP alpha com una plataforma immunoterapèutica prometedora que aprofita la immunitat humoral preexistent. El tercer capítol experimental descriu una nova immunoteràpia mediada per antígens exògens basada en la proteïna hemaglutinina (H) del virus de la xarampió. La proteïna H és un antigen altament immunogènic en humans a causa de la vacunació generalitzada contra el virus de la pallola. Es van formular LNP que codifiquen la proteïna H i es va demostrar que transfecten eficaçment tant cultius cel·lulars cancerosos bidimensionals com esferoides tumorals tridimensionals. A més, l'administració in vivo de LNP H en ratolins vacunats contra la pallola amb tumors de melanoma B16-BL6 va donar lloc a una disminució significativa del creixement tumoral. Aquest efecte terapèutic està associat amb una forta infiltració intratumoral de limfòcits T citotòxics CD8+, un canvi en la proporció de cèl·lules T CD8/CD4 i la producció ex vivo de citocines proinflamatòries després de la reactivació de l'antigen, característiques distintives d'una potent resposta immunitària mediada per cèl·lules T CD8+. En conjunt, aquests resultats posen en relleu el potencial de LNP H com a nova estratègia per millorar la immunogenicitat tumoral i provocar fortes respostes immunitàries antitumorals. Esperem que els resultats obtinguts en aquesta tesi doctoral demostren la versatilitat de les plataformes basades en LNP i recolzen el desenvolupament d'immunoteràpies innovadores contra el càncer., This research was supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020-119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovación and by the European Regional Development Fund—A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from “la Caixa” Foundation under agreement LCF/PR/SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Smart Nanoparticles for Enhanced Melanoma Therapy: From Controlled Drug Release to Self-Propelled Nanomotors

  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
[ES] La presente tesis doctoral, titulada "Nanopartículas inteligentes para una terapia mejorada contra el melanoma: desde la liberación controlada de fármacos a los nanomotores autopropulsados", se centra en el desarrollo de estrategias terapéuticas innovadoras frente al melanoma mediante nanopartículas inteligentes. En concreto, aborda la síntesis, caracterización y evaluación de nanodispositivos para la liberación controlada de fármacos. Estos sistemas buscan superar barreras características del melanoma, como la evasión inmunitaria, la matriz extracelular tumoral y la degradación prematura de los fármacos, reduciendo los efectos adversos sobre tejidos sanos. El primer capítulo presenta una introducción al cáncer y, especialmente, al melanoma, describiendo sus principales características biológicas, mecanismos de metástasis y evasión inmune. Asimismo, revisa la evolución de las estrategias terapéuticas y las limitaciones que condicionan su eficacia. Posteriormente, se introduce la nanotecnología aplicada a la medicina y sus principales aplicaciones oncológicas. Finalmente, se analizan los sistemas de liberación controlada de fármacos, las profármacos y los estímulos capaces de desencadenar su activación, con especial atención a las nanoestrellas de oro y a las nanopartículas mesoporosas de sílice como plataformas prometedoras para el tratamiento del melanoma. El capítulo segundo se exponen los objetivos de la tesis. El tercer capítulo describe una plataforma nanoterapéutica bioortogonal basada en nanoestrellas de oro para la fotoactivación controlada de profármacos de doxorrubicina mediante luz infrarroja cercana (NIR). Se desarrollaron dos estrategias complementarias: una prodroga de doxorrubicina inactivada mediante grupos 2-nitrobencilo y la misma molécula anclada covalentemente a la superficie de las nanoestrellas. La irradiación NIR induce la liberación controlada de la doxorrubicina activa. Ambas formulaciones mostraron elevada estabilidad en condiciones fisiológicas y activación exclusivamente tras irradiación. Además, se demostró la activación intracelular del profármaco en células de melanoma y cáncer de cuello uterino minimizando los efectos fototérmicos. Los estudios in vitro e in vivo en modelos murinos de melanoma evidenciaron una liberación eficiente del fármaco, una inhibición significativa del crecimiento tumoral y una actividad terapéutica selectiva únicamente bajo irradiación NIR. El cuarto capítulo se centra en el desarrollo de nanomotores autopropulsados para mejorar la distribución de fármacos en regiones profundas del tumor. El sistema se basa en nanopartículas Janus de platino funcionalizadas con lactato oxidasa y cargadas con doxorrubicina. Estas aprovechan el lactato del microambiente tumoral como combustible endógeno, proporcionando propulsión autónoma y depleción metabólica. Los nanomotores mostraron movimiento autónomo y liberación específica del fármaco en condiciones fisiológicas. En células de melanoma produjeron una marcada reducción de la viabilidad celular a bajas concentraciones, mientras que en esferoides tumorales alcanzaron una penetración intratumoral superior a la de sistemas pasivos. Los estudios in vivo demostraron una reducción significativa del tamaño tumoral y un aumento de la infiltración de linfocitos CD8+, sugiriendo una disminución de la evasión inmunitaria asociada al metabolismo del lactato. Finalmente, los capítulos quinto y sexto recogen la discusión general, las perspectivas futuras y las conclusiones. En conjunto, los resultados demuestran la versatilidad de las nanoestrellas plasmónicas y de los nanomotores impulsados por metabolitos como plataformas para terapias antitumorales innovadoras. Estas estrategias combinan activación controlada de profármacos, propulsión autónoma y remodelación del microambiente tumoral para mejorar la administración de fármacos frente al melanoma y otros tumores accesibles., [EN] The present doctoral thesis, entitled "Smart nanoparticles for improved melanoma therapy: from controlled drug release to self-propelled nanomotors", focuses on the development of innovative therapeutic strategies against melanoma through the use of smart nanoparticles. Specifically, it addresses the synthesis, characterization, and evaluation of nanodevices for controlled drug release. These systems are designed to overcome key barriers associated with melanoma, such as immune evasion, the tumor extracellular matrix, and premature drug degradation, while reducing adverse effects on healthy tissues. The first chapter provides an introduction to cancer, and especially to melanoma, describing its main biological features, mechanisms of metastasis, and immune evasion. It also reviews the evolution of therapeutic strategies and the limitations that affect their efficacy. Subsequently, the application of nanotechnology in medicine and its main oncological applications are introduced. Finally, controlled drug delivery systems, prodrugs, and the stimuli capable of triggering their activation are analyzed, with special attention to gold nanostars and mesoporous silica nanoparticles as promising platforms for melanoma treatment. The second chapter presents the objectives of the thesis. The third chapter describes a bioorthogonal nanotherapeutic platform based on gold nanostars for the controlled photoactivation of doxorubicin prodrugs using near-infrared (NIR) light. Two complementary strategies were developed: a doxorubicin prodrug inactivated by 2-nitrobenzyl groups and the same molecule covalently anchored to the surface of the nanostars. NIR irradiation induces the controlled release of active doxorubicin. Both formulations showed high stability under physiological conditions and were activated only upon irradiation. In addition, intracellular activation of the prodrug was demonstrated in melanoma and cervical cancer cells, minimizing photothermal effects. In vitro and in vivo studies in murine melanoma models showed efficient drug release, significant inhibition of tumor growth, and selective therapeutic activity only under NIR irradiation. The fourth chapter focuses on the development of self-propelled nanomotors to improve drug distribution in deep tumor regions. The system is based on platinum Janus nanoparticles functionalized with lactate oxidase and loaded with doxorubicin. These nanoparticles exploit lactate from the tumor microenvironment as an endogenous fuel, providing autonomous propulsion and metabolic depletion. The nanomotors showed self-propulsion and specific drug release under physiological conditions. In melanoma cells, they produced a marked reduction in cell viability at low concentrations, while in tumor spheroids they achieved greater intratumoral penetration than passive systems. In vivo studies demonstrated a significant reduction in tumor size and an increase in CD8+ lymphocyte infiltration, suggesting a decrease in immune evasion associated with lactate metabolism. Finally, the fifth and sixth chapters present the general discussion, future perspectives, and conclusions. Overall, the results demonstrate the versatility of plasmonic nanostars and metabolite-driven nanomotors as platforms for innovative anticancer therapies. These strategies combine controlled prodrug activation, autonomous propulsion, and remodeling of the tumor microenvironment to improve drug delivery against melanoma and other accessible tumors., [CA] La present tesi doctoral, titulada "Nanopartícules intel·ligents per a una teràpia millorada contra el melanoma: des de l'alliberament controlat de fàrmacs fins als nanomotors autopropulsats", se centra en el desenvolupament d'estratègies terapèutiques innovadores contra el melanoma mitjançant l'ús de nanopartícules intel·ligents. En concret, aborda la síntesi, la caracterització i l'avaluació de nanodispositius per a l'alliberament controlat de fàrmacs. Aquests sistemes busquen superar barreres característiques del melanoma, com ara l'evasió immunitària, la matriu extracel·lular tumoral i la degradació prematura dels fàrmacs, reduint els efectes adversos sobre els teixits sans. El primer capítol presenta una introducció al càncer i, especialment, al melanoma, descrivint-ne les principals característiques biològiques, els mecanismes de metàstasi i l'evasió immune. Així mateix, revisa l'evolució de les estratègies terapèutiques i les limitacions que en condicionen l'eficàcia. Posteriorment, s'introdueix la nanotecnologia aplicada a la medicina i les seues principals aplicacions oncològiques. Finalment, s'analitzen els sistemes d'alliberament controlat de fàrmacs, els profàrmacs i els estímuls capaços de desencadenar-ne l'activació, amb una atenció especial a les nanoestrelles d'or i a les nanopartícules mesoporoses de sílice com a plataformes prometedores per al tractament del melanoma. El segon capítol exposa els objectius de la tesi. El tercer capítol descriu una plataforma nanoterapèutica bioortogonal basada en nanoestrelles d'or per a la fotoactivació controlada de profàrmacs de doxorubicina mitjançant llum infraroja pròxima (NIR). Es van desenvolupar dues estratègies complementàries: un profàrmac de doxorubicina inactivat mitjançant grups 2-nitrobenzil i la mateixa molècula ancorada covalentment a la superfície de les nanoestrelles. La irradiació NIR indueix l'alliberament controlat de la doxorubicina activa. Ambdues formulacions van mostrar una elevada estabilitat en condicions fisiològiques i una activació exclusivament després de la irradiació. A més, es va demostrar l'activació intracel·lular del profàrmac en cèl·lules de melanoma i de càncer de coll uterí, minimitzant els efectes fototèrmics. Els estudis in vitro i in vivo en models murins de melanoma van evidenciar un alliberament eficient del fàrmac, una inhibició significativa del creixement tumoral i una activitat terapèutica selectiva únicament sota irradiació NIR. El quart capítol se centra en el desenvolupament de nanomotors autopropulsats per a millorar la distribució de fàrmacs en regions profundes del tumor. El sistema es basa en nanopartícules Janus de platí funcionalitzades amb lactat oxidasa i carregades amb doxorubicina. Aquestes aprofiten el lactat del microambient tumoral com a combustible endogen, proporcionant propulsió autònoma i depleció metabòlica. Els nanomotors van mostrar moviment autònom i alliberament específic del fàrmac en condicions fisiològiques. En cèl·lules de melanoma van produir una reducció marcada de la viabilitat cel·lular a baixes concentracions, mentre que en esferoides tumorals van assolir una penetració intratumoral superior a la dels sistemes passius. Els estudis in vivo van demostrar una reducció significativa de la mida tumoral i un augment de la infiltració de limfòcits CD8+, la qual cosa suggereix una disminució de l'evasió immunitària associada al metabolisme del lactat. Finalment, els capítols cinqué i sisé recullen la discussió general, les perspectives futures i les conclusions. En conjunt, els resultats demostren la versatilitat de les nanoestrelles plasmòniques i dels nanomotors impulsats per metabolits com a plataformes per a teràpies antitumorals innovadores. Aquestes estratègies combinen activació controlada de profàrmacs, propulsió autònoma i remodelació del microambient tumoral per a millorar l'administració de fàrmacs davant del melanoma i altres tumors accessibles., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22 and PID2024-155683OB-C41, funded by MCIN/AEI/10.13039/501100011033 and by the European Regional Development Fund (ERDF) – A way of doing Europe; by the Generalitat Valenciana (Project PROMETEO CIPROM/2021/007); by Project MFA/2022/049 from the Advanced Materials programme, funded by the European Union NextGenerationEU (PRTR-C17.I1); and by the Generalitat Valenciana and the European Research Council (ERC) via Advanced Grant 101052997 (EDISON). This research was also supported by CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. J.J.E.-M. thanks the AECC Scientific Foundation, and especially the AECC Council of Valencia, for their PhD grant (PRDVA21651ESTE). P.D. thanks the AECC Scientific Foundation for their postdoctoral grant (INVES246470DIEZ). O.F.S. acknowledges the support from the Provincial Council of Gipuzkoa under the Fellows Gipuzkoa programme. F.J.H. thanks MIU for his FPU grant (FPU20/06021). V.S.-A. thanks MIU for his FPI grant (PRE2022-103714). A.G-F. and P.D. thank the Instituto de Salud Carlos III and the European Social Fund for their "Miguel Servet" contracts (CP25/00067 and CP24/00043). The authors thank the UPV Electron Microscopy Service and the CIPF Confocal and Electron Microscopy Services for their technical support. The U26 NMR: Biomedical Applications II platform from NANBIOSIS (ICTS "NANBIOSIS", Research Infrastructures & Services of CIBER-BBN) is also gratefully acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A Renal Clearable Probe for In Vivo Monoamine Oxidase (MAO) Detection

  • Domínguez-Rodríguez, Marcia|||0000-0002-0635-0699
  • Azorín-Soriano, David
  • García-Fleitas, Jessie
  • Soriano-Teruel, Paula
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Lerida-Viso, Araceli
  • Soler-Beatty, Jennifer
  • Rodrigo-Martínez, Paula
  • Pau Arroyo Máñez
  • Rojas-Vázquez, Sara
  • Fariñas, Isabel
  • Blandez, Juan F.
[EN] Hyperactivation of monoamine oxidase enzymes (MAO) is associated with uncontrolled production of neurotoxic compounds such as reactive oxygen species, whose accumulation is linked to neurodegenerative, chronic, and age-related diseases. Although chromo-fluorogenic probes for detecting and quantifying MAO activity have been reported, non-invasive methods for monitoring MAO overexpression in vivo remain elusive. Here, we report a renal-clearable fluorogenic probe based on the cyanine-7 fluorophore (Cy7-MAO) for in vivo detection of MAO overexpression through a simple measurement of the fluorescence in urine. The probe incorporates sulfonic acid moieties for renal clearance and a propylamino group as a MAO substrate. Upon administration, Cy7-MAO is hydrolysed at the site by MAO, releasing a highly emissive Cy7 fluorophore, which is excreted in urine and quantified by fluorescence. Cy7-MAO is validated in vitro using HepG2 liver human cells, which express elevated MAO levels. We further demonstrate the in vivo applicability of Cy7-MAO for MAO activity monitoring in aged mice, which show significantly higher urine fluorescence than young mice, consistent with an elevated MAO activity in older animals. These findings support Cy7-MAO as a tool for longitudinal assessment of MAO activity in vivo, providing a novel approach to study MAO-related pathologies., This research was supported by projects PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2024-155683OB-C41, funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund A way of doing Europe, and CIPROM/2021/007, funded by Generalitat Valenciana (GVA), to R. M-M., and PID2020-117937GB-I00 to I.F. The authors acknowledge the financial support from the FEDER found of the European Union (IDIFEDER/2021/044). This research also wassupported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB06/01/2012 and CB06/05/0086), Instituto de Salud Carlos III, MCIN. This study was also supported by the project PAID06-24 funded by Universitat Politècnica de València. J. F. B. thanks the support from the la Caixa Foundation (ID 100010434) under the fellowship code LCF/BQ/PR24/12050022. D. A. -S. thanks his predoctoral fellowship CIACIF from GVA (CIACIF/2022/132). J. G. -F. thanks his predoctoral fellowship GRISOLIA from GVA (GRISOLIAP/2021/122) A.G-F. thanks the Instituto de Salud Carlos III and the European Social Fund for financial support Miguel Servet (CP25/00067).